Watch the Dallas Symposium LIVE, and fundraiser auction
Ticket proceeds support mindat.org! - click here...
Log InRegister
Quick Links : The Mindat ManualThe Rock H. Currier Digital LibraryMindat Newsletter [Free Download]
Home PageAbout MindatThe Mindat ManualHistory of MindatCopyright StatusWho We AreContact UsAdvertise on Mindat
Donate to MindatCorporate SponsorshipSponsor a PageSponsored PagesMindat AdvertisersAdvertise on Mindat
Learning CenterWhat is a mineral?The most common minerals on earthInformation for EducatorsMindat ArticlesThe ElementsThe Rock H. Currier Digital LibraryGeologic Time
Minerals by PropertiesMinerals by ChemistryAdvanced Locality SearchRandom MineralRandom LocalitySearch by minIDLocalities Near MeSearch ArticlesSearch GlossaryMore Search Options
Search For:
Mineral Name:
Locality Name:
Keyword(s):
 
The Mindat ManualAdd a New PhotoRate PhotosLocality Edit ReportCoordinate Completion ReportAdd Glossary Item
Mining CompaniesStatisticsUsersMineral MuseumsClubs & OrganizationsMineral Shows & EventsThe Mindat DirectoryDevice SettingsThe Mineral Quiz
Photo SearchPhoto GalleriesSearch by ColorNew Photos TodayNew Photos YesterdayMembers' Photo GalleriesPast Photo of the Day GalleryPhotography

(2019, February) Reactions Weekly Vol. 1738 (1) Springer Science and Business Media LLC

Advanced
   -   Only viewable:
Reference TypeJournal (issue)
JournalReactions Weekly
Year2019 (February)Volume1738
Issue1
PublisherSpringer Science and Business Media LLC
Mindat Ref. ID13378895Long-form Identifiermindat:1:5:13378895:4
GUID0
Full Reference(2019, February) Reactions Weekly Vol. 1738 (1) Springer Science and Business Media LLC
Plain Text(2019, February) Reactions Weekly Vol. 1738 (1) Springer Science and Business Media LLC
In(2019) Reactions Weekly Vol. 1738. Springer Science and Business Media LLC

Contains

1 2
Page 1 of 2		Next Page
(2019) Carbimazole/thiamazole linked with malformations, pancreatitis. Reactions Weekly, 1738 (1) 1 doi:10.1007/s40278-019-57375-z
(2019) OA/RA capsules pulled from Australian shelves. Reactions Weekly, 1738 (1) 2 doi:10.1007/s40278-019-57376-z
(2019) Risk of Fournier's gangrene with SGLT2 inhibitors. Reactions Weekly, 1738 (1) 3 doi:10.1007/s40278-019-57377-z
(2019) Adverse events with 9-valent HPV vaccine during pregnancy. Reactions Weekly, 1738 (1) 4 doi:10.1007/s40278-019-57378-z
(2019) Baricitinib for RA: cardiovascular disorders and VTE. Reactions Weekly, 1738 (1) 5 doi:10.1007/s40278-019-57379-z
(2019) Implementation rates of STOPP/START recommendations. Reactions Weekly, 1738 (1) 6 doi:10.1007/s40278-019-57380-y
(2019) Increased bleeding risk with aspirin in patients without CVD. Reactions Weekly, 1738 (1) 7 doi:10.1007/s40278-019-57381-y
(2019) Risk of falling with anticholinergic drugs. Reactions Weekly, 1738 (1) 8 doi:10.1007/s40278-019-57382-y
(2019) Tamoxifen for male breast cancer: thrombotic event risk. Reactions Weekly, 1738 (1) 9 doi:10.1007/s40278-019-57383-y
(2019) Ruellia bahiensis. Reactions Weekly, 1738 (1) 10 doi:10.1007/s40278-019-57384-y
(2019) Abacavir/dolutegravir/lamivudine. Reactions Weekly, 1738 (1) 11 doi:10.1007/s40278-019-57385-y
(2019) Abatacept/methotrexate. Reactions Weekly, 1738 (1) 12 doi:10.1007/s40278-019-57386-y
(2019) Afatinib. Reactions Weekly, 1738 (1) 13 doi:10.1007/s40278-019-57387-y
(2019) Alectinib. Reactions Weekly, 1738 (1) 14 doi:10.1007/s40278-019-57388-y
(2019) Alemtuzumab. Reactions Weekly, 1738 (1) 15 doi:10.1007/s40278-019-57389-y
(2019) Alteplase. Reactions Weekly, 1738 (1) 16 doi:10.1007/s40278-019-57390-x
(2019) Alteplase. Reactions Weekly, 1738 (1) 17 doi:10.1007/s40278-019-57391-x
(2019) Aminocaproic-acid. Reactions Weekly, 1738 (1) 18 doi:10.1007/s40278-019-57392-x
(2019) Amiodarone. Reactions Weekly, 1738 (1) 19 doi:10.1007/s40278-019-57393-x
(2019) Amiodarone/flecainide. Reactions Weekly, 1738 (1) 20 doi:10.1007/s40278-019-57394-x
(2019) Amiodarone/rivaroxaban interaction. Reactions Weekly, 1738 (1) 21 doi:10.1007/s40278-019-57395-x
(2019) Amphotericin B liposomal/posaconazole/voriconazole. Reactions Weekly, 1738 (1) 22 doi:10.1007/s40278-019-57396-x
(2019) Amphotericin-b-liposomal. Reactions Weekly, 1738 (1) 23 doi:10.1007/s40278-019-57397-x
(2019) Anlotinib. Reactions Weekly, 1738 (1) 24 doi:10.1007/s40278-019-57398-x
(2019) Anti-CD138-CAR-transduced-T-cells/bb-2121. Reactions Weekly, 1738 (1) 25 doi:10.1007/s40278-019-57399-x
(2019) Antibacterials. Reactions Weekly, 1738 (1) 26 doi:10.1007/s40278-019-57400-4
(2019) Antiepileptic-drugs. Reactions Weekly, 1738 (1) 27 doi:10.1007/s40278-019-57401-4
(2019) Antineoplastic. Reactions Weekly, 1738 (1) 28 doi:10.1007/s40278-019-57402-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 29 doi:10.1007/s40278-019-57403-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 30 doi:10.1007/s40278-019-57404-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 31 doi:10.1007/s40278-019-57405-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 32 doi:10.1007/s40278-019-57406-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 33 doi:10.1007/s40278-019-57407-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 34 doi:10.1007/s40278-019-57408-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 35 doi:10.1007/s40278-019-57409-4
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 36 doi:10.1007/s40278-019-57410-3
(2019) Antineoplastics. Reactions Weekly, 1738 (1) 37 doi:10.1007/s40278-019-57411-3
(2019) Antineoplastics interaction. Reactions Weekly, 1738 (1) 38 doi:10.1007/s40278-019-57412-3
(2019) Antineoplastics/clarithromycin. Reactions Weekly, 1738 (1) 39 doi:10.1007/s40278-019-57413-3
(2019) Antineoplastics/folinic acid. Reactions Weekly, 1738 (1) 40 doi:10.1007/s40278-019-57414-3
(2019) Antipsychotics/thiamazole. Reactions Weekly, 1738 (1) 41 doi:10.1007/s40278-019-57415-3
(2019) Antithymocyte-globulin/ciclosporin. Reactions Weekly, 1738 (1) 42 doi:10.1007/s40278-019-57416-3
(2019) Antithymocyte-globulin/ciclosporin/quinine. Reactions Weekly, 1738 (1) 43 doi:10.1007/s40278-019-57417-3
(2019) Anxiolytics/linezolid/trazodone interaction. Reactions Weekly, 1738 (1) 44 doi:10.1007/s40278-019-57418-3
(2019) Apixaban/dabigatran etexilate/rivaroxaban. Reactions Weekly, 1738 (1) 45 doi:10.1007/s40278-019-57419-3
(2019) Argatroban/heparin. Reactions Weekly, 1738 (1) 46 doi:10.1007/s40278-019-57420-2
(2019) Aripiprazole. Reactions Weekly, 1738 (1) 47 doi:10.1007/s40278-019-57421-2
(2019) Ascorbic acid. Reactions Weekly, 1738 (1) 48 doi:10.1007/s40278-019-57422-2
(2019) Aspirin. Reactions Weekly, 1738 (1) 49 doi:10.1007/s40278-019-57423-2
(2019) Atenolol. Reactions Weekly, 1738 (1) 50 doi:10.1007/s40278-019-57424-2
(2019) Azacitidine. Reactions Weekly, 1738 (1) 51 doi:10.1007/s40278-019-57425-2
(2019) Azathioprine/rituximab/tacrolimus. Reactions Weekly, 1738 (1) 52 doi:10.1007/s40278-019-57426-2
(2019) BCG vaccine. Reactions Weekly, 1738 (1) 53 doi:10.1007/s40278-019-57427-2
(2019) Bendamustine. Reactions Weekly, 1738 (1) 54 doi:10.1007/s40278-019-57428-2
(2019) Bendamustine/rituximab. Reactions Weekly, 1738 (1) 55 doi:10.1007/s40278-019-57429-2
(2019) Benzodiazepines/diazepam. Reactions Weekly, 1738 (1) 56 doi:10.1007/s40278-019-57430-1
(2019) Bevacizumab. Reactions Weekly, 1738 (1) 57 doi:10.1007/s40278-019-57431-1
(2019) Bevacizumab. Reactions Weekly, 1738 (1) 58 doi:10.1007/s40278-019-57432-1
(2019) Blinatumomab. Reactions Weekly, 1738 (1) 59 doi:10.1007/s40278-019-57433-1
(2019) Bortezomib. Reactions Weekly, 1738 (1) 60 doi:10.1007/s40278-019-57434-1
(2019) Bortezomib/dexamethasone. Reactions Weekly, 1738 (1) 61 doi:10.1007/s40278-019-57435-1
(2019) Botulinum-toxin-a. Reactions Weekly, 1738 (1) 62 doi:10.1007/s40278-019-57436-1
(2019) Brentuximab vedotin/nivolumab. Reactions Weekly, 1738 (1) 63 doi:10.1007/s40278-019-57437-1
(2019) Brodalumab. Reactions Weekly, 1738 (1) 64 doi:10.1007/s40278-019-57438-1
(2019) Bufexamac/chlorhexidine/lidocaine. Reactions Weekly, 1738 (1) 65 doi:10.1007/s40278-019-57439-1
(2019) Bupivacaine/epinephrine/fentanyl. Reactions Weekly, 1738 (1) 66 doi:10.1007/s40278-019-57440-0
(2019) Bupropion. Reactions Weekly, 1738 (1) 67 doi:10.1007/s40278-019-57441-0
(2019) Capecitabine. Reactions Weekly, 1738 (1) 68 doi:10.1007/s40278-019-57442-0
(2019) Carbamazepine/ledipasvir/sofosbuvir interaction. Reactions Weekly, 1738 (1) 69 doi:10.1007/s40278-019-57443-0
(2019) Carbimazole/levothyroxine-sodium. Reactions Weekly, 1738 (1) 70 doi:10.1007/s40278-019-57444-0
(2019) Cefazolin. Reactions Weekly, 1738 (1) 71 doi:10.1007/s40278-019-57445-0
(2019) Cefazolin/ciprofloxacin. Reactions Weekly, 1738 (1) 72 doi:10.1007/s40278-019-57446-0
(2019) Cefazolin/daptomycin. Reactions Weekly, 1738 (1) 73 doi:10.1007/s40278-019-57447-0
(2019) Ceftaroline fosamil. Reactions Weekly, 1738 (1) 74 doi:10.1007/s40278-019-57448-0
(2019) Ceftriaxone. Reactions Weekly, 1738 (1) 75 doi:10.1007/s40278-019-57449-0
(2019) Ceftriaxone/hydroxyzine. Reactions Weekly, 1738 (1) 76 doi:10.1007/s40278-019-57450-z
(2019) Cetuximab. Reactions Weekly, 1738 (1) 77 doi:10.1007/s40278-019-57451-z
(2019) Chlorhexidine. Reactions Weekly, 1738 (1) 78 doi:10.1007/s40278-019-57452-z
(2019) Cibenzoline. Reactions Weekly, 1738 (1) 79 doi:10.1007/s40278-019-57453-z
(2019) Ciclosporin. Reactions Weekly, 1738 (1) 80 doi:10.1007/s40278-019-57454-z
(2019) Cisplatin. Reactions Weekly, 1738 (1) 81 doi:10.1007/s40278-019-57455-z
(2019) Cisplatin/etoposide. Reactions Weekly, 1738 (1) 82 doi:10.1007/s40278-019-57456-z
(2019) Cisplatin/fluorouracil. Reactions Weekly, 1738 (1) 83 doi:10.1007/s40278-019-57457-z
(2019) Cisplatin/gemcitabine. Reactions Weekly, 1738 (1) 84 doi:10.1007/s40278-019-57458-z
(2019) Cisplatin/irinotecan. Reactions Weekly, 1738 (1) 85 doi:10.1007/s40278-019-57459-z
(2019) Cisplatin/nivolumab/vinorelbine. Reactions Weekly, 1738 (1) 86 doi:10.1007/s40278-019-57460-y
(2019) Clobetasol/desonide/triamcinolone. Reactions Weekly, 1738 (1) 87 doi:10.1007/s40278-019-57461-y
(2019) Clofarabine/cytarabine. Reactions Weekly, 1738 (1) 88 doi:10.1007/s40278-019-57462-y
(2019) Clopidogrel/heparin. Reactions Weekly, 1738 (1) 89 doi:10.1007/s40278-019-57463-y
(2019) Cloxacillin. Reactions Weekly, 1738 (1) 90 doi:10.1007/s40278-019-57464-y
(2019) Clozapine. Reactions Weekly, 1738 (1) 91 doi:10.1007/s40278-019-57465-y
(2019) Colistin/meropenem. Reactions Weekly, 1738 (1) 92 doi:10.1007/s40278-019-57466-y
(2019) Corticosteroids/cyclophosphamide/rituximab. Reactions Weekly, 1738 (1) 93 doi:10.1007/s40278-019-57467-y
(2019) Cotrimoxazole. Reactions Weekly, 1738 (1) 94 doi:10.1007/s40278-019-57468-y
(2019) Crizotinib. Reactions Weekly, 1738 (1) 95 doi:10.1007/s40278-019-57469-y
(2019) Cyanoacrylate. Reactions Weekly, 1738 (1) 96 doi:10.1007/s40278-019-57470-x
(2019) Cyclophosphamide/dexamethasone/doxorubicin liposomal. Reactions Weekly, 1738 (1) 97 doi:10.1007/s40278-019-57471-x
(2019) Dabigatran etexilate. Reactions Weekly, 1738 (1) 98 doi:10.1007/s40278-019-57472-x
(2019) Dabigatran-etexilate. Reactions Weekly, 1738 (1) 99 doi:10.1007/s40278-019-57473-x
(2019) Dabrafenib/nivolumab/trametinib. Reactions Weekly, 1738 (1) 100 doi:10.1007/s40278-019-57474-x
(2019) Dantrolene/paracetamol. Reactions Weekly, 1738 (1) 101 doi:10.1007/s40278-019-57475-x
(2019) Dasatinib/nilotinib. Reactions Weekly, 1738 (1) 102 doi:10.1007/s40278-019-57476-x
(2019) Dasatinib/sorafenib. Reactions Weekly, 1738 (1) 103 doi:10.1007/s40278-019-57477-x
(2019) Deferasirox. Reactions Weekly, 1738 (1) 104 doi:10.1007/s40278-019-57478-x
(2019) Dexamethasone. Reactions Weekly, 1738 (1) 105 doi:10.1007/s40278-019-57479-x
(2019) Dexmedetomidine. Reactions Weekly, 1738 (1) 106 doi:10.1007/s40278-019-57480-9
(2019) Dexmedetomidine. Reactions Weekly, 1738 (1) 107 doi:10.1007/s40278-019-57481-9
(2019) Digoxin. Reactions Weekly, 1738 (1) 108 doi:10.1007/s40278-019-57482-9
(2019) Docetaxel. Reactions Weekly, 1738 (1) 109 doi:10.1007/s40278-019-57483-9
(2019) Docetaxel/nintedanib. Reactions Weekly, 1738 (1) 110 doi:10.1007/s40278-019-57484-9
(2019) Dolutegravir/emtricitabine/tenofovir-alafenamide. Reactions Weekly, 1738 (1) 111 doi:10.1007/s40278-019-57485-9
(2019) Doxorubicin/doxorubicin liposomal. Reactions Weekly, 1738 (1) 112 doi:10.1007/s40278-019-57486-9
(2019) Doxorubicin/etoposide interaction. Reactions Weekly, 1738 (1) 113 doi:10.1007/s40278-019-57487-9
(2019) Dulaglutide. Reactions Weekly, 1738 (1) 114 doi:10.1007/s40278-019-57488-9
(2019) Edoxaban. Reactions Weekly, 1738 (1) 115 doi:10.1007/s40278-019-57489-9
(2019) Eltrombopag. Reactions Weekly, 1738 (1) 116 doi:10.1007/s40278-019-57490-8
(2019) Emtricitabine/raltegravir/tenofovir. Reactions Weekly, 1738 (1) 117 doi:10.1007/s40278-019-57491-8
(2019) Enzalutamide. Reactions Weekly, 1738 (1) 118 doi:10.1007/s40278-019-57492-8
(2019) Erlotinib/gefitinib. Reactions Weekly, 1738 (1) 119 doi:10.1007/s40278-019-57493-8
(2019) Estramustine phosphate sodium/toremifene. Reactions Weekly, 1738 (1) 120 doi:10.1007/s40278-019-57494-8
(2019) Etanercept. Reactions Weekly, 1738 (1) 121 doi:10.1007/s40278-019-57495-8
(2019) Everolimus. Reactions Weekly, 1738 (1) 122 doi:10.1007/s40278-019-57496-8
(2019) Fentanyl. Reactions Weekly, 1738 (1) 123 doi:10.1007/s40278-019-57497-8
(2019) Flecainide. Reactions Weekly, 1738 (1) 124 doi:10.1007/s40278-019-57498-8
(2019) Fluconazole/isavuconazole. Reactions Weekly, 1738 (1) 125 doi:10.1007/s40278-019-57499-8
(2019) Fluorouracil. Reactions Weekly, 1738 (1) 126 doi:10.1007/s40278-019-57500-2
(2019) Fluorouracil/folinic acid/oxaliplatin. Reactions Weekly, 1738 (1) 127 doi:10.1007/s40278-019-57501-2
(2019) Fluticasone propionate/lopinavir/ritonavir interaction. Reactions Weekly, 1738 (1) 128 doi:10.1007/s40278-019-57502-2
(2019) Gefitinib/osimertinib. Reactions Weekly, 1738 (1) 129 doi:10.1007/s40278-019-57503-2
(2019) Gemcitabine/nivolumab. Reactions Weekly, 1738 (1) 130 doi:10.1007/s40278-019-57504-2
(2019) Golimumab. Reactions Weekly, 1738 (1) 131 doi:10.1007/s40278-019-57505-2
(2019) Heparin. Reactions Weekly, 1738 (1) 132 doi:10.1007/s40278-019-57506-2
(2019) Heparin. Reactions Weekly, 1738 (1) 133 doi:10.1007/s40278-019-57507-2
(2019) Heparin. Reactions Weekly, 1738 (1) 134 doi:10.1007/s40278-019-57508-2
(2019) Human papillomavirus vaccine recombinant nonavalent merck. Reactions Weekly, 1738 (1) 135 doi:10.1007/s40278-019-57509-2
(2019) Hydrocortisone/risperidone/sodium chloride. Reactions Weekly, 1738 (1) 136 doi:10.1007/s40278-019-57510-1
(2019) Hydroxycarbamide. Reactions Weekly, 1738 (1) 137 doi:10.1007/s40278-019-57511-1
(2019) Hydroxycarbamide. Reactions Weekly, 1738 (1) 138 doi:10.1007/s40278-019-57512-1
(2019) Hydroxycarbamide. Reactions Weekly, 1738 (1) 139 doi:10.1007/s40278-019-57513-1
(2019) Hydroxycarbamide. Reactions Weekly, 1738 (1) 140 doi:10.1007/s40278-019-57514-1
(2019) Hydroxychloroquine. Reactions Weekly, 1738 (1) 141 doi:10.1007/s40278-019-57515-1
(2019) Hydroxychloroquine. Reactions Weekly, 1738 (1) 142 doi:10.1007/s40278-019-57516-1
(2019) Ibrutinib. Reactions Weekly, 1738 (1) 143 doi:10.1007/s40278-019-57517-1
(2019) Ibrutinib. Reactions Weekly, 1738 (1) 144 doi:10.1007/s40278-019-57518-1
(2019) Ibrutinib. Reactions Weekly, 1738 (1) 145 doi:10.1007/s40278-019-57519-1
(2019) Ibrutinib/obinutuzumab. Reactions Weekly, 1738 (1) 146 doi:10.1007/s40278-019-57520-0
(2019) Imatinib. Reactions Weekly, 1738 (1) 147 doi:10.1007/s40278-019-57521-0
(2019) Immunosuppressants. Reactions Weekly, 1738 (1) 148 doi:10.1007/s40278-019-57522-0
(2019) Immunosuppressants. Reactions Weekly, 1738 (1) 149 doi:10.1007/s40278-019-57523-0
(2019) Immunosuppressants/bortezomib. Reactions Weekly, 1738 (1) 150 doi:10.1007/s40278-019-57524-0
(2019) Immuosuppressants. Reactions Weekly, 1738 (1) 151 doi:10.1007/s40278-019-57525-0
(2019) Insulin aspart/thiamazole. Reactions Weekly, 1738 (1) 152 doi:10.1007/s40278-019-57526-0
(2019) Interferon alpha 2b. Reactions Weekly, 1738 (1) 153 doi:10.1007/s40278-019-57527-0
(2019) Ipilimumab. Reactions Weekly, 1738 (1) 154 doi:10.1007/s40278-019-57528-0
(2019) Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly, 1738 (1) 155 doi:10.1007/s40278-019-57529-0
(2019) Irinotecan. Reactions Weekly, 1738 (1) 156 doi:10.1007/s40278-019-57530-z
(2019) Isoniazid/linezolid. Reactions Weekly, 1738 (1) 157 doi:10.1007/s40278-019-57531-z
(2019) Isoprenaline. Reactions Weekly, 1738 (1) 158 doi:10.1007/s40278-019-57532-z
(2019) Lactobacillus rhamnosus. Reactions Weekly, 1738 (1) 159 doi:10.1007/s40278-019-57533-z
(2019) Lactobacillus rhamnosus. Reactions Weekly, 1738 (1) 160 doi:10.1007/s40278-019-57534-z
(2019) Lamotrigine. Reactions Weekly, 1738 (1) 161 doi:10.1007/s40278-019-57535-z
(2019) Lamotrigine/valproate. Reactions Weekly, 1738 (1) 162 doi:10.1007/s40278-019-57536-z
(2019) Lenalidomide. Reactions Weekly, 1738 (1) 163 doi:10.1007/s40278-019-57537-z
(2019) Lenvatinib. Reactions Weekly, 1738 (1) 164 doi:10.1007/s40278-019-57538-z
(2019) Letrozole/palbociclib. Reactions Weekly, 1738 (1) 165 doi:10.1007/s40278-019-57539-z
(2019) Levodopa. Reactions Weekly, 1738 (1) 166 doi:10.1007/s40278-019-57540-y
(2019) Levofloxacin. Reactions Weekly, 1738 (1) 167 doi:10.1007/s40278-019-57541-y
(2019) Lidocaine. Reactions Weekly, 1738 (1) 168 doi:10.1007/s40278-019-57542-y
(2019) Linagliptin. Reactions Weekly, 1738 (1) 169 doi:10.1007/s40278-019-57543-y
(2019) Linezolid. Reactions Weekly, 1738 (1) 170 doi:10.1007/s40278-019-57544-y
(2019) Loperamide abuse/withdrawal. Reactions Weekly, 1738 (1) 171 doi:10.1007/s40278-019-57545-y
(2019) Measles-mumps-and-rubella-virus-vaccine-(priorix)/Meningococcal-vaccine-group-C-conjugate/Varicella-zoster-virus-vaccine-live. Reactions Weekly, 1738 (1) 172 doi:10.1007/s40278-019-57546-y
(2019) Medroxyprogesterone. Reactions Weekly, 1738 (1) 173 doi:10.1007/s40278-019-57547-y
(2019) Melphalan. Reactions Weekly, 1738 (1) 174 doi:10.1007/s40278-019-57548-y
(2019) Meropenem. Reactions Weekly, 1738 (1) 175 doi:10.1007/s40278-019-57549-y
(2019) Metformin. Reactions Weekly, 1738 (1) 176 doi:10.1007/s40278-019-57550-x
(2019) Metformin/norepinephrine. Reactions Weekly, 1738 (1) 177 doi:10.1007/s40278-019-57551-x
(2019) Methotrexate. Reactions Weekly, 1738 (1) 178 doi:10.1007/s40278-019-57552-x
(2019) Methotrexate. Reactions Weekly, 1738 (1) 179 doi:10.1007/s40278-019-57553-x
(2019) Methotrexate/prednisone. Reactions Weekly, 1738 (1) 180 doi:10.1007/s40278-019-57554-x
(2019) Methylprednisolone. Reactions Weekly, 1738 (1) 181 doi:10.1007/s40278-019-57555-x
(2019) Metoprolol. Reactions Weekly, 1738 (1) 182 doi:10.1007/s40278-019-57556-x
(2019) Mianserin. Reactions Weekly, 1738 (1) 183 doi:10.1007/s40278-019-57557-x
(2019) Minocycline. Reactions Weekly, 1738 (1) 184 doi:10.1007/s40278-019-57558-x
(2019) Morphine. Reactions Weekly, 1738 (1) 185 doi:10.1007/s40278-019-57559-x
(2019) Multiple drugs. Reactions Weekly, 1738 (1) 186 doi:10.1007/s40278-019-57560-9
(2019) Multiple drugs. Reactions Weekly, 1738 (1) 187 doi:10.1007/s40278-019-57561-9
(2019) Multiple drugs. Reactions Weekly, 1738 (1) 188 doi:10.1007/s40278-019-57562-9
(2019) Multiple drugs. Reactions Weekly, 1738 (1) 189-190 doi:10.1007/s40278-019-57563-9
(2019) Mupirocin/pimecrolimus. Reactions Weekly, 1738 (1) 190 doi:10.1007/s40278-019-57564-9
(2019) Mycophenolate mofetil/prednisolone/tacrolimus. Reactions Weekly, 1738 (1) 191 doi:10.1007/s40278-019-57565-9
(2019) Mycophenolate mofetil/prednisone/tacrolimus. Reactions Weekly, 1738 (1) 192 doi:10.1007/s40278-019-57566-9
(2019) Nivolumab. Reactions Weekly, 1738 (1) 193 doi:10.1007/s40278-019-57567-9
(2019) Nivolumab. Reactions Weekly, 1738 (1) 194 doi:10.1007/s40278-019-57568-9
(2019) Nivolumab. Reactions Weekly, 1738 (1) 195 doi:10.1007/s40278-019-57569-9
(2019) Nivolumab. Reactions Weekly, 1738 (1) 196 doi:10.1007/s40278-019-57570-8
(2019) Nivolumab. Reactions Weekly, 1738 (1) 197 doi:10.1007/s40278-019-57571-8
(2019) Norethisterone/oxaliplatin. Reactions Weekly, 1738 (1) 198 doi:10.1007/s40278-019-57572-8
(2019) Octenidine/phenoxyethanol. Reactions Weekly, 1738 (1) 199 doi:10.1007/s40278-019-57573-8
(2019) Omalizumab. Reactions Weekly, 1738 (1) 200 doi:10.1007/s40278-019-57574-8
(2019) Opioids. Reactions Weekly, 1738 (1) 201 doi:10.1007/s40278-019-57575-8
(2019) Oxaliplatin. Reactions Weekly, 1738 (1) 202 doi:10.1007/s40278-019-57576-8
(2019) Oxaliplatin. Reactions Weekly, 1738 (1) 203 doi:10.1007/s40278-019-57577-8
(2019) Oxycodone. Reactions Weekly, 1738 (1) 204 doi:10.1007/s40278-019-57578-8
(2019) Oxycodone/oxycodone/paracetamol abuse. Reactions Weekly, 1738 (1) 205 doi:10.1007/s40278-019-57579-8
(2019) Pamidronic acid/zoledronic acid. Reactions Weekly, 1738 (1) 206 doi:10.1007/s40278-019-57580-7
(2019) Pasireotide/pegvisomant. Reactions Weekly, 1738 (1) 207 doi:10.1007/s40278-019-57581-7
(2019) PEG-3350/phytomenadione. Reactions Weekly, 1738 (1) 208 doi:10.1007/s40278-019-57582-7
(2019) Pegaspargase. Reactions Weekly, 1738 (1) 209 doi:10.1007/s40278-019-57583-7
(2019) Pembrolizumab. Reactions Weekly, 1738 (1) 210 doi:10.1007/s40278-019-57584-7
(2019) Penicillamine. Reactions Weekly, 1738 (1) 211 doi:10.1007/s40278-019-57585-7
(2019) Pentobarbital overdose. Reactions Weekly, 1738 (1) 212 doi:10.1007/s40278-019-57586-7
(2019) Phenobarbital overdose. Reactions Weekly, 1738 (1) 213 doi:10.1007/s40278-019-57587-7
(2019) Phenylephrine. Reactions Weekly, 1738 (1) 214 doi:10.1007/s40278-019-57588-7
(2019) Phenytoin/sodium valproate. Reactions Weekly, 1738 (1) 215 doi:10.1007/s40278-019-57589-7
(2019) Piperacillin/tazobactam/teicoplanin. Reactions Weekly, 1738 (1) 216 doi:10.1007/s40278-019-57590-6
(2019) Plasma. Reactions Weekly, 1738 (1) 217 doi:10.1007/s40278-019-57591-6
(2019) Posaconazole. Reactions Weekly, 1738 (1) 218 doi:10.1007/s40278-019-57592-6
(2019) Potassium chloride. Reactions Weekly, 1738 (1) 219 doi:10.1007/s40278-019-57593-6
(2019) Potassium-chloride. Reactions Weekly, 1738 (1) 220 doi:10.1007/s40278-019-57594-6
(2019) Praziquantel. Reactions Weekly, 1738 (1) 221 doi:10.1007/s40278-019-57595-6
(2019) Prednisolone. Reactions Weekly, 1738 (1) 222 doi:10.1007/s40278-019-57596-6
(2019) Prednisolone. Reactions Weekly, 1738 (1) 223 doi:10.1007/s40278-019-57597-6
(2019) Prednisolone. Reactions Weekly, 1738 (1) 224 doi:10.1007/s40278-019-57598-6
(2019) Prednisone. Reactions Weekly, 1738 (1) 225 doi:10.1007/s40278-019-57599-6
(2019) Propofol/sevoflurane/suxamethonium chloride. Reactions Weekly, 1738 (1) 226 doi:10.1007/s40278-019-57600-0
(2019) Propylthiouracil. Reactions Weekly, 1738 (1) 227 doi:10.1007/s40278-019-57601-0
(2019) Prothrombin complex concentrate/warfarin. Reactions Weekly, 1738 (1) 228 doi:10.1007/s40278-019-57602-0
(2019) Risperidone. Reactions Weekly, 1738 (1) 229 doi:10.1007/s40278-019-57603-0
(2019) Risperidone. Reactions Weekly, 1738 (1) 230 doi:10.1007/s40278-019-57604-0
(2019) Ritonavir/triamcinolone interaction. Reactions Weekly, 1738 (1) 231 doi:10.1007/s40278-019-57605-0
(2019) Rituximab. Reactions Weekly, 1738 (1) 232 doi:10.1007/s40278-019-57606-0
(2019) Rituximab. Reactions Weekly, 1738 (1) 233 doi:10.1007/s40278-019-57607-0
(2019) Rituximab. Reactions Weekly, 1738 (1) 234 doi:10.1007/s40278-019-57608-0
(2019) Rivaroxaban. Reactions Weekly, 1738 (1) 235 doi:10.1007/s40278-019-57609-0
(2019) Romiplostim. Reactions Weekly, 1738 (1) 236 doi:10.1007/s40278-019-57610-z
(2019) Ropivacaine. Reactions Weekly, 1738 (1) 237 doi:10.1007/s40278-019-57611-z
(2019) Ropivacaine. Reactions Weekly, 1738 (1) 238 doi:10.1007/s40278-019-57612-z
(2019) Ropivacaine overdose. Reactions Weekly, 1738 (1) 239 doi:10.1007/s40278-019-57613-z
(2019) Ruxolitinib. Reactions Weekly, 1738 (1) 240 doi:10.1007/s40278-019-57614-z
(2019) Ruxolitinib. Reactions Weekly, 1738 (1) 241 doi:10.1007/s40278-019-57615-z
(2019) Sacubitril/valsartan. Reactions Weekly, 1738 (1) 242 doi:10.1007/s40278-019-57616-z
(2019) Sevelamer. Reactions Weekly, 1738 (1) 243 doi:10.1007/s40278-019-57617-z
(2019) Sodium valproate. Reactions Weekly, 1738 (1) 244 doi:10.1007/s40278-019-57618-z
(2019) Sofosbuvir. Reactions Weekly, 1738 (1) 245 doi:10.1007/s40278-019-57619-z
(2019) Suxamethonium chloride. Reactions Weekly, 1738 (1) 246 doi:10.1007/s40278-019-57620-y
(2019) Tacrolimus. Reactions Weekly, 1738 (1) 247 doi:10.1007/s40278-019-57621-y
(2019) Tacrolimus. Reactions Weekly, 1738 (1) 248 doi:10.1007/s40278-019-57622-y
(2019) Terbinafine. Reactions Weekly, 1738 (1) 249 doi:10.1007/s40278-019-57623-y
(2019) Teriflunomide. Reactions Weekly, 1738 (1) 250 doi:10.1007/s40278-019-57624-y
1 2
Page 1 of 2		Next Page

See Also

These are possibly similar items as determined by title/reference text matching only.

(2019, February) Reactions Weekly Vol. 1739 (1) Springer Science and Business Media LLC
(2019, February) Reactions Weekly Vol. 1740 (1) Springer Science and Business Media LLC
(2019, February) Reactions Weekly Vol. 1741 (1) Springer Science and Business Media LLC
(2017, February) Reactions Weekly Vol. 1637 (1) Springer Science and Business Media LLC
(2016, February) Reactions Weekly Vol. 1587 (1) Springer Science and Business Media LLC
(2016, February) Reactions Weekly Vol. 1588 (1) Springer Science and Business Media LLC
(2016, February) Reactions Weekly Vol. 1589 (1) Springer Science and Business Media LLC
(2016, February) Reactions Weekly Vol. 1590 (1) Springer Science and Business Media LLC
(2012, February) Reactions Weekly Vol. 1387 (1) Springer Science and Business Media LLC
(2013, February) Reactions Weekly Vol. 1437 (1) Springer Science and Business Media LLC
(2013, February) Reactions Weekly Vol. 1438 (1) Springer Science and Business Media LLC
 
and/or  
Mindat.org is an outreach project of the Hudson Institute of Mineralogy, a 501(c)(3) not-for-profit organization.
Copyright © mindat.org and the Hudson Institute of Mineralogy 1993-2025, except where stated. Most political location boundaries are Β© OpenStreetMap contributors. Mindat.org relies on the contributions of thousands of members and supporters. Founded in 2000 by Jolyon Ralph.
To cite: Ralph, J., Von Bargen, D., Martynov, P., Zhang, J., Que, X., Prabhu, A., Morrison, S. M., Li, W., Chen, W., & Ma, X. (2025). Mindat.org: The open access mineralogy database to accelerate data-intensive geoscience research. American Mineralogist, 110(6), 833–844. doi:10.2138/am-2024-9486.
Privacy Policy - Terms & Conditions - Contact Us / DMCA issues - Report a bug/vulnerability Current server date and time: August 19, 2025 14:54:46
Go to top of page